Dr. Reddy's Laboratories announces the launch of Capecitabine Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.

Dr. Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4695.8 as compared to the previous close of Rs. 4710.2. The total number of shares traded during the day was 29943 in over 3046 trades.

The stock hit an intraday high of Rs. 4759.85 and intraday low of 4670.4. The net turnover during the day was Rs. 140964320.

Source : Equity Bulls

Keywords